SURFACE OPHTHALMICS
Surface Ophthalmics is a pharmaceutical company that develops therapeutics for the treatment of ocular diseases. The company's current drug pipeline consists of three proprietary drug candidates, all utilizing Klarity, a patented delivery vehicle. Surface Ophthalmics was founded in 2017 and is based in Pleasanton, California.
SURFACE OPHTHALMICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Pleasanton, California, United States
Country:
United States
Website Url:
http://www.surfaceophthalmics.com
Total Employee:
1+
Status:
Active
Total Funding:
40 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API WordPress Font Awesome ReCAPTCHA Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
AevisBio
AevisBio is a biotech company that develops therapeutics for neurological and immunological disorders.
Alaya Bioscience
Alaya Bioscience is a biotech company that develops novel nanotherapeutics for the treatment of human diseases.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arpeggio Bio
Arpeggio builds technology to watch and learn how drugs work.
Panavance Therapeutics
Panavance Therapeutics is a clinical-stage pharmaceutical company that develops novel therapeutics for effective cancer treatments.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sunomix Therapeutics
Sunomix Therapeutics is a biopharmaceutical company that produces antibody drug conjugates and nanoparticules for the treatment of cancer.
Zymedi
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.surfaceophthalmics.com
Unable to get host informations!!!
More informations about "Surface Ophthalmics"
About Us - Surface Ophthalmics
About Us About Surface Ophthalmics Founded in 2018, Surface Ophthalmics (Surface) stands as a pioneering biopharmaceutical firm devoted to the discovery and market introduction of advanced treatments for diseases affecting the …See details»
Surface Ophthalmics Company Profile 2024: Valuation, Funding ...
Surface Ophthalmics General Information Description. Developer of novel therapeutics designed to treat ocular diseases. The company's therapeutics utilize topical formulations with a delivery …See details»
Surface Ophthalmics - Crunchbase Company Profile & Funding
Surface Ophthalmics is a pharmaceutical company that develops therapeutics for the treatment of ocular diseases. The company's current drug pipeline consists of three proprietary drug …See details»
Surface Ophthalmics - LinkedIn
Founded in 2018, Surface Ophthalmics (Surface) stands as a pioneering biopharmaceutical firm devoted to the discovery and market introduction of advanced treatments for diseases …See details»
Surface Ophthalmics Company Profile | Management and
Surface Ophthalmics Profile and History . Surface Ophthalmics, Inc., based in Pleasanton, CA, is a pharmaceutical company focused on development and commercialization of innovative …See details»
Surface Ophthalmics, Inc. Company Profile -Sales, Contacts, …
Surface Ophthalmics, Inc. is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately (7) years.See details»
Surface Ophthalmics - Craft
Surface Ophthalmics $40 m in total funding,. See insights on Surface Ophthalmics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Surface Ophthalmics - VentureRadar
Similar Companies: Mati Therapeutics USA Privately Held Headquartered in Austin, Texas, Mati Therapeutics is developing a non-invasive sustained drug delivery platform to treat ocular …See details»
Surface Ophthalmics Overview - Salary.com
Discover essential details about Surface Ophthalmics, including address, contact, and journey of our company's evolution.See details»
Surface Ophthalmics Announces $25 Million Private Round of …
PLEASANTON, Calif., July 21, 2021 /PRNewswire/ -- Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative …See details»
Surface Ophthalmics' Landmark Chronic Dry Eye Study Reaches …
May 6, 2021 ABOUT OUR CLINCIAL PROGRAMS Surface Ophthalmics is advancing three clinical programs: one in chronic dry eye disease (SURF-100), one in acute dry eye disease …See details»
Surface Ophthalmics Announces New Leadership with Richard …
Our mission is to address critical unmet needs in eye care by harnessing in-depth expertise, a dynamic strategy, operational efficiency, and distinctive clinical advantages. To learn more …See details»
Surface Ophthalmics Announces $25 Million Private Round of …
Jul 21, 2021 News Surface Ophthalmics Announces $25 Million Private Round of Fundraising Proceeds from the capital raise will help to support and advance Surface’s ongoing clinical …See details»
Surface Ophthalmics Announces First Patient Dosed in Landmark …
Jan 27, 2021 News Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease Innovative head-to-head study …See details»
Surface Ophthalmics' Landmark Chronic Dry Eye Study Reaches …
May 6, 2021 Surface Ophthalmics' Landmark Chronic Dry Eye Study Reaches 50% Enrollment Milestone First-ever head-to-head study in chronic dry eye disease, comparing SURF-100 …See details»
Surface Ophthalmics Announces First Patient Dosed in Phase II …
PLEASANTON, Calif., Feb. 4, 2021 /PRNewswire/ -- Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for …See details»
Surface Ophthalmics Announces First Patient Dosed in Phase II …
News Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye SURF-200 leverages the proven Klarity vehicle and betamethasone …See details»
News - Surface Ophthalmics
Jan 27, 2021 News News View the latest company news from Surface Ophthalmics. July 21, 2021 Surface Ophthalmics Announces $25 Million Private Round of Fundraising Read full …See details»
Surface Ophthalmics Announces First Patient Dosed in Landmark …
Jan 27, 2021 Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease Innovative head-to-head study will …See details»